Primel reveals positive results for Active Hand Coating to combat hospital-acquired infections
Primel, a pioneer in the realm of infection prevention solutions, has announced remarkable results from a recent study, confirming the superior sporicidal activity of its Active Hand Coating. Demonstrating more than 99.99% efficacy with a short contact time of just 30 seconds against Clostridium difficile (C. diff), this innovation is set to revolutionize the global healthcare system, which annually grapples with costs estimated at $1.7 billion due to C. diff infections. These infections not only impose a significant financial strain but also contribute to the escalating challenge of hospital-acquired infections (HAIs), highlighting the need for more effective prevention strategies.
Clostridium difficile infections are a formidable challenge in healthcare settings, primarily due to their resistance to existing antibiotics and their ability to cause severe complications. Primel’s Active Hand Coating emerges as the first product to kill C. diff spores in as little as 30 seconds, showcasing the longest continuous residual activity known to date. The coating’s effectiveness was rigorously tested according to the European standard EN 17126, marking a significant milestone in the fight against a broad spectrum of pathogens, including both Gram-positive and Gram-negative bacteria, enveloped and non-enveloped viruses, yeast, and spores.
The study’s findings underscore the potential of Primel’s Active Hand Coating to significantly reduce pathogen transmission rates, thereby enhancing operational excellence and evolving safety protocols for both staff and patients. Notably, a care home study revealed that the coating’s effectiveness was immediately apparent, surpassing that of standard hand sanitizers by 23%, and maintained a 70% effectiveness after one hour, marking a 45% improvement over conventional options.
Prof. Mark Wilcox and Dr. Sajinder Luthra, leading figures in the study, emphasize the critical need for innovative solutions in combating HAIs and antibiotic-resistant pathogens. Prof. Wilcox points out the dire consequences of these infections on healthcare resources, while Dr. Luthra highlights Primel’s Active Hand Coating as a groundbreaking advance in sustained microbial protection, addressing the global challenge of antibiotic resistance.
At the core of Primel’s Active Hand Coating is TridAnt, a technology developed by strategic partner BioInteractions, which has been instrumental in creating a coating capable of eradicating difficult pathogens like C. diff within seconds. This innovation not only offers hope in the battle against HAIs but also paves the way for a new era in infection prevention, where the spread of harmful pathogens can be effectively curtailed.
As healthcare systems worldwide continue to face the growing threat of HAIs and antibiotic resistance, Primel’s Active Hand Coating represents a beacon of hope. This breakthrough underscores the importance of continuous innovation and the development of effective infection prevention solutions that can safeguard patient health and support healthcare providers.